Vor biopharma names matthew r. patterson as chairman and promotes tania philipp

Cambridge, mass., june 11, 2021 (globe newswire) -- vor biopharma (nasdaq: vor or the company), a cell therapy company pioneering engineered hematopoietic stem cell (ehsc) therapies to be used in combination with targeted therapies for the treatment of cancer, today announced matthew r. patterson as chairman of its board of directors.
VOR Ratings Summary
VOR Quant Ranking